Cantor Fitzgerald Comments on Cytokinetics FY2025 Earnings
Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Cytokinetics in a ...
BioPharma Dive8h
Ascentage prices first biotech IPO of 2025, raising $126M
The China-based cancer drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.
Hosted on MSN16h
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study
Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart failure ...
Astria Therapeutics Receives Buy Rating Due to Promising Clinical Developments and Strategic Market Positioning
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Astria Therapeutics (ATXS – Research Report), with ...